Interaction Between Cancer Metabolic Reprogramming and Immune Response
DOI:
https://doi.org/10.61173/ejbtc229Keywords:
Cancer cell, metabolic reprogramming, tumor microenvironment, immune systemAbstract
Cancer cells undergo metabolic reprogramming to adapt to the harsh tumor microenvironment, allowing for their rapid proliferation and high survival rates. Metabolic reprogramming is one of the top ten characteristics of tumors and plays a key role in promoting tumorigenesis and progression. Glucose metabolism disorders are the most representative metabolic features. Unlike normal cells that rely on oxidative phosphorylation under aerobic conditions, cancer cells predominantly utilize aerobic glycolysis, a phenomenon known as the Warburg effect. This shift in metabolism in cancer cells not only enhances ATP production but also generates metabolites like lactate that may lead to an acidic tumor microenvironment (TME), which could further promote the proliferation and invasion of cancer cells. Metabolites like lactate, glutamine, arginine, tryptophan, and cholesterol not only provide energy and build blocks for cancer cells but also reprogram immune cell responses, facilitating immune evasion. This review explores the complex interactions between cancer cell metabolism and the immune system, highlighting how metabolites of cancer cells modulate immune responses and contribute to cancer progression. Understanding these interactions can provide insights into potential therapeutic strategies that target both cancer metabolism and immune evasion mechanisms.References
[1] Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., Liang, J., Tang, Y., Su, M., Luo, X., Yang, Y., Shi, Y., Wang, H., Zhou, Y., & Liao, Q. (2021). The cancer metabolic reprogramming and immune response. Molecular Cancer, 20(1), 28. 10.1186/s12943-021-01316-8
[2] Mak, T. W., Cairns, R. A., & Harris, I. S. (2011). Regulation of cancer cell metabolism. Nature Reviews.Cancer, 11(2), 85– 95. 10.1038/nrc2981
[3] McCarthy, S. A., Mufson, R. A., Pearce, E. J., Rathmell, J. C., & Howcroft, T. K. (2013). Metabolic reprogramming of the immune response in the tumor microenvironment. Cancer Biology & Therapy, 14(4), 315–318. 10.4161/cbt.23616
[4] Mosier, J. A., Schwager, S. C., Boyajian, D. A., & Reinhart- King, C. A. (2021). Cancer cell metabolic plasticity in migration and metastasis. Clinical & Experimental Metastasis, 38(4), 343–359.
[5] Hu, C., Xuan, Y., Zhang, X., Liu, Y., Yang, S., & Yang, K. (2022). Immune cell metabolism and metabolic reprogramming. Molecular Biology Reports, 49(10), 9783–9795. 10.1007/ s11033-022-07474-2
[6] Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021 Jul 13;11(17):8322-8336.
[7] DeBerardinis, R. J., & Chandel, N. S. (2020). We need to talk about the warburg effect. Nature Metabolism, 2(2), 127–129. 10.1038/s42255-020-0172-2
[8] Domiński, A., Krawczyk, M., Konieczny, T., Kasprów, M., Foryś, A., Pastuch-Gawołek, G., & Kurcok, P. (2020). Biodegradable pH-responsive micelles loaded with 8-hydroxyquinoline glycoconjugates for warburg effect based tumor targeting. European Journal of Pharmaceutics and Biopharmaceutics, 154, 317–329. 10.1016/j.ejpb.2020.07.019
[9] Jiang, P., Du, W., & Wu, M. (2014). Regulation of the pentose phosphate pathway in cancer. Protein & Cell, 5(8), 592– 602. 10.1007/s13238-014-0082-8
[10] Ge, T., Yang, J., Zhou, S., Wang, Y., Li, Y., & Tong, X. (2020). The role of the pentose phosphate pathway in diabetes and cancer. Frontiers in Endocrinology (Lausanne), 11, 365. 10.3389/fendo.2020.00365
[11] Mattaini, K. R., Sullivan, M. R., & Vander Heiden, M.,G. (2016). The importance of serine metabolism in cancer. The Journal of Cell Biology, 214(3), 249–257. 10.1083/ jcb.201604085
[12] Yang, M., & Vousden, K. H. (2016). Serine and one-carbon metabolism in cancer. Nature Reviews.Cancer, 16(10), 650–662. 10.1038/nrc.2016.81
[13] Romero-Garcia, S., Moreno-Altamirano, M., Prado-Garcia, H., & Sánchez-García, F. J. (2016). Lactate contribution to the tumor microenvironment: Mechanisms, effects on immune cells and therapeutic relevance. Frontiers in Immunology, 7, 52. 10.3389/fimmu.2016.00052
[14] Multhoff, G., & Vaupel, P. (2021). Lactate-avid regulatory T cells: Metabolic plasticity controls immunosuppression in tumour microenvironment. Signal Transduction and Targeted Therapy, 6(1), 171. 10.1038/s41392-021-00598-0
[15] Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves- Deal R, et al. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. Transl Oncol. 2020;13(10):100828. doi: 10.1016/j.tranon.2020.100828.
[16] Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients. 2018 Oct 23;10(11):1564. doi: 10.3390/nu10111564. PMID: 30360490; PMCID: PMC6266414.
[17] Li T, Copeland C, Le A. Glutamine Metabolism in Cancer. Adv Exp Med Biol. 2021;1311:17-38. doi: 10.1007/978-3-030- 65768-0_2. PMID: 34014532; PMCID: PMC9703266.
[18] Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013–21. doi: 10.1126/science.aav2588.
[19] Chen, C., Hsu, S., Ann, D. K., Yen, Y., & Kung, H. (2021). Arginine signaling and cancer metabolism. Cancers, 13(14), 3541. 10.3390/cancers13143541
[20] Davel LE, Jasnis MA, de la Torre E, Gotoh T, Diament M, Magenta G, et al. Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett. 2002;532(1–2):216–20. doi: 10.1016/S0014- 5793(02)03682-7.
[21] Martí i Líndez, A., & Reith, W. (2021a). Arginine-dependent Dean&Francis ISSN 2959-409X immune responses. Cellular and Molecular Life Sciences : CMLS, 78(13), 5303–5324. 10.1007/s00018-021-03828-4
[22] Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016;167(3):829–42. doi: 10.1016/j.cell.2016.09.031.
[23] Günther, J., Fallarino, F., Fuchs, D., & Wirthgen, E. (2020). Editorial: Immunomodulatory roles of tryptophan metabolites in inflammation and cancer. Frontiers in Immunology, 11, 1497. 10.3389/fimmu.2020.01497
[24] Perez‐Castro, L., Garcia, R., Venkateswaran, N., Barnes, S., & Conacci‐Sorrell, M. (2023). Tryptophan and its metabolites in normal physiology and cancer etiology. The FEBS Journal, 290(1), 7–27. 10.1111/febs.16245
[25] Huang, B., Song, B., & Xu, C. (2020a). Cholesterol metabolism in cancer: Mechanisms and therapeutic opportunities. Nature Metabolism, 2(2), 132–141. 10.1038/ s42255-020-0174-0
[26] Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, et al. The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. J Immunother. 2020;43(6):196–203. doi: 10.1097/ CJI.0000000000000321.
[27] Phelps CC, Vadia S, Boyaka PN, Varikuti S, Attia Z, Dubey P, et al. A listeriolysin O subunit vaccine is protective against Listeria monocytogenes. Vaccine. 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
